The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof； and(ii) at least one of docosahexaenoic acid (22:6； DHA), eicosapentaenoic acid (20:5； EPA) and docosapentaenoic acid (22:5； DPA), or esters thereof； and (iii) vitamin C and/or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and/or slowing down brain atrophy in a human subject in need thereof.
